Fermenta Biotech Reports Strong Financial Growth and Improved Operational Efficiency in December 2024 Results

Fermenta Biotech has recently reported its financial results for the quarter ending December 2024, showcasing a notable performance in the pharmaceuticals and drugs sector. The company's score has undergone an adjustment in evaluation, reflecting a shift from 19 to 32 over the past three months. The financial data reveals significant growth in key metrics. Profit Before Tax less Other Income (PBT) reached Rs 43.11 crore, marking a substantial year-on-year increase of 218.15%. Similarly, Profit After Tax (PAT) stood at Rs 36.91 crore, demonstrating a remarkable growth of 274.7% year-on-year. Net Sales also showed a strong performance, totaling Rs 156.47 crore, which is a 58.10% increase compared to the previous year. Additionally, Fermenta Biotech has maintained a low Debt-Equity Ratio of 0.43 times, indicating a consistent reduction in borrowing relative to equity capital. The company achieved its highest Operating Profit at Rs 53.27 crore and Operating Profit Margin at 34.04%, reflecting improved operational efficiency. Earnings per Share (EPS) also reached a peak of Rs 12.66, highlighting the company's ability to generate higher earnings for its shareholders. For further insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.